Our Science
Redefining immunotherapy with validated solutions
Overview
The human immune system works well most of the time. When it is disrupted due to infection, treatment tends to target the infection, but the immune system remains susceptible.
The World Health Organization (WHO) names antibiotic resistance as one of the biggest threats facing humanity. Antibiotic resistance threatens global health, food security, and development. A growing number of infections are becoming harder to treat as antibiotics used to treat them become less effective and more and more classes of antibiotics have become completely ine ective. Antibiotic resistance leads to longer hospital stays, higher medical costs and increased mortality.
The human immune system works well most of the time. When it is disrupted due to infection, treatment tends to target the infection, but the immune system remains susceptible.
The World Health Organization (WHO) names antibiotic resistance as one of the biggest threats facing humanity.
Infectious Disease Programs
Histogen is developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to protect the immune function. Currently, the Histogen lead drug candidate, emricasan, is about to begin a clinical trial evaluating the use of emricasan for bacterial skin infections including those related to MRSA. Emricasan has already shown positive clinical results showing signifiacnt reduction in symptoms in subjects infected with COVID-19.
Intended application and benefits
Gram-positive bacterial skin infections
Gram-negative bacterial skin infections
Viral infections including COVID-19